Skip to main content

Table 1 Clinical characteristics in patients with FMD <4.2 % and ≥4.2 %

From: Prognostic significance of endothelial dysfunction in patients undergoing percutaneous coronary intervention in the era of drug-eluting stents

  FMD <4.2 % (n = 40 ) FMD ≥ 4.2 % (n = 40) p
Age (years) 69.5 ± 7.1 69.4 ± 7.3 0.96
Female gender, n (%) 34 (85.0) 30 (75.0) 0.26
Body mass index 25.1 ± 3.4 23.6 ± 3.3 0.06
Diabetes mellitus, n (%) 23 (57.5) 22 (55.0) 0.82
Hypertension, n (%) 27 (65.7) 27 (67.5) 1.00
Dyslipidemia, n (%) 22 (55.0) 31 (77.5) 0.03
Current smoking, n (%) 10 (25.0) 11 (27.5) 0.80
Chronic renal insufficiency, n (%) 16 (40.0) 19 (47.5) 0.50
Previous PCI, n (%) 5 (12.5) 10 (25.0) 0.15
Previous myocardial infarction, n (%) 2 (5.0) 2 (5.0) 1.00
HDL cholesterol (mg/dl) 43.8 ± 11.2 49.3 ± 12.3 0.04
LDL cholesterol (mg/dl) 87.8 ± 28.1 88.1 ± 24.6 0.96
Triglycerides (mg/dl) 142.9 ± 73.6 113.7 ± 61.6 0.06
MDA-LDL cholesterol 97.9 ± 36.8 (n = 33) 82.2 ± 32.0 (n = 27) 0.62
Adiponectin 11.3 ± 5.2 12.0 ± 5.3 0.90
Medications    
Aspirin, n (%) 40 (100) 38 (95.0) 0.15
Clopidogrel, n (%) 35 (87.5) 33 (82.5) 0.53
ACE inhibitor/ARB, n (%) 35 (87.5) 30 (75.0) 0.15
ARB, n (%) 31 (77.5) 25 (62.5) 0.22
ACE inhibitors, n (%) 4 (10.0) 5 (12.5) 0.99
Perindopril 2 (5.0) 1 (2.5) 0.99
Imidapril 2 (5.0) 4 (10.0) 0.67
Statins, n (%) 36 (90.0) 36 (90.0) 1.00
Atorvastatin 4 (10.0) 7 (17.5) 0.52
Rosuvastatin 18 (45.0) 16 (40.0) 0.82
Pitavastaitn 14 (35.0) 13 (32.5) 0.99
β-blockers, n (%) 21 (52.5) 25(62.5) 0.37
  1. Data are expressed as mean ± SD or number (percentage)
  2. FMD Flow-mediated dilation, PCI Percutaneous coronary intervention, HDL High-density lipoprotein, LDL low-density lipoprotein, MDA-LDL Malondialdehyde-modified low-density lipoprotein, ACE Angiotensin-converting enzyme, ARB Angiotensin II receptor blocker